MMC’s Senior Management Team consists of:
Evan Steeg Ph.D., Founder, President & CEO. Dr. Steeg has directed Molecular Mining Corporation’s initial financing, set-up, recruiting, R&D; and business development. Previous industrial experience includes the design of data mining solutions in engineering and protein design at E.I. du Pont de Nemours & Co. He holds a B.A. in mathematics (with Distinction in All Subjects) from Cornell University and an M.Sc. and Ph.D. in computer science from the University of Toronto.
Roland Somogyi Ph.D., Chief Scientific Officer. Dr. Somogyi has over ten years of experience in academic, government and industry research, most recently as Director of Neurobiology at Incyte Pharmaceuticals. A recognized leader in the area of gene networks and pathways based on gene expression data, he is frequently called upon as an invited speaker at international meetings in computational biology, genomics and neuroscience and has organized a number of conference symposia. He holds an M.Sc. in biology and a Ph.D. in biophysics and physiology (summa cum laude) from the University of Konstanz, Germany.
Ken Arnold, VP Corporate Strategy and Finance. From his experience in building a $200m consumer data mining company, he has a highly experienced skill set in financial management, general management, strategic partnering, and licensing of intellectual property. Mr. Arnold has a B.Sc. in chemical engineering from the University of Waterloo and an M.B.A. from York University.
Don Van Dyke, VP Marketing and Sales. Mr. Van Dyke brings to MMC over twenty years of experience in sales, marketing and general management in the healthcare, biotechnology and computer technology markets. After seven years at American Hospital Supply, he joined the start-up Bio Image Corporation in 1986 as VP North American Sales. He became General Manager after building their direct sales team. At Millipore he was world-wide Imaging Markets Manager for product lines including automated DNA sequencers, DNA typing and mapping software, and proteomics systems. He was CEO of B.I. Systems Corporation after leading a management buy out of Bio Image from Millipore in 1997. He holds a B.A. (cum laude) from Duke University.
Lynn Caporale Ph.D., VP New Business Development. Dr. Caporale has broad experience in the pharmaceutical, biotech and functional genomics sectors, gained through over a decade at Merck, and 6 years as a strategic advisor to a number of pre-IPO stage companies. She helped start CombiChem, works as an independent consultant, and currently serves on the Board of Directors and/or Scientific Advisory Boards of several other biotechnology companies. She has a B.S. Honors (magna cum laude) in chemistry from the City University of New York and a Ph.D. in molecular biology from the University of California at Berkeley.